MCID: ACT020
MIFTS: 35

Acute T Cell Leukemia malady

Categories: Cancer diseases, Immune diseases, Blood diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acute T Cell Leukemia

Aliases & Descriptions for Acute T Cell Leukemia:

Name: Acute T Cell Leukemia 12 14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 69
Precursor T-Cell Lymphoblastic Lymphoma 69
T-Cell Acute Lymphoblastic Leukemia 12
Leukemia T-Cell Acute Lymphoblastic 29
Precursor T Lymphoblastic Leukemia 12
Leukemia, Acute T-Cell 13

Classifications:



External Ids:

Disease Ontology 12 DOID:5603
ICD10 33 C91.5 C91.50
MeSH 42 D015459
NCIt 47 C3184
UMLS 69 C0023493

Summaries for Acute T Cell Leukemia

MalaCards based summary : Acute T Cell Leukemia, also known as precursor t-cell lymphoblastic leukemia-lymphoma, is related to precursor t-cell acute lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with Acute T Cell Leukemia is HSD17B1 (Hydroxysteroid 17-Beta Dehydrogenase 1). The drugs Arranon and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include t cells, endothelial and b cells.

Related Diseases for Acute T Cell Leukemia

Graphical network of the top 20 diseases related to Acute T Cell Leukemia:



Diseases related to Acute T Cell Leukemia

Symptoms & Phenotypes for Acute T Cell Leukemia

Drugs & Therapeutics for Acute T Cell Leukemia

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 46 NELARABINE GlaxoSmithKline Approved October 2005

Drugs for Acute T Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 547)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
5
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
6
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
9
Idarubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58957-92-9 42890
10
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
11
Teniposide Approved Phase 4,Phase 2 29767-20-2 34698
12
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
13
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
14
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
15
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
16
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
17
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
18
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
20
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
21
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
22
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
24
Azacitidine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 320-67-2 9444
25
Decitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2353-33-5 451668
26
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
27
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
28
Arsenic trioxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1327-53-3 518740
29
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
30
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
31
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130167-69-0
32
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
33
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
34
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
35
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
36
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1 75614-87-8, 51-45-6 774
37
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
38
Diphenhydramine Approved Phase 4,Phase 2 58-73-1, 147-24-0 3100
39
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216503-57-0
40
Promethazine Approved Phase 4,Phase 2 60-87-7 4927
41
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 1 4291-63-8 20279
42
Pancrelipase Approved Phase 4,Phase 1 53608-75-6
43
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
44
Epirubicin Approved Phase 4 56420-45-2 41867
45
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
47
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 302-79-4 5538
48
Butyric Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264
49
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
50
Aclarubicin Investigational Phase 4 57576-44-0 451415

Interventional clinical trials:

(show top 50) (show all 1254)
id Name Status NCT ID Phase
1 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4
2 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4
3 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
4 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
5 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
6 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4
7 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
8 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4
9 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4
10 The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Completed NCT02953730 Phase 4
11 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4
12 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Recruiting NCT02290132 Phase 4
13 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
14 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4
15 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4
16 Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS Recruiting NCT01540812 Phase 4
17 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4
18 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4
19 Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation Active, not recruiting NCT00331162 Phase 4
20 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3
21 Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00707083 Phase 3
22 Treatment of Acute Lymphoblastic Leukemia in Children Unknown status NCT00400946 Phase 3
23 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT01085617 Phase 3
24 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma Unknown status NCT00003728 Phase 3
25 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3
26 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
27 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
28 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3
29 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3
30 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
31 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3
32 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3
33 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma Completed NCT01230983 Phase 3
34 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3
35 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3
36 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00613457 Phase 3
37 Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed NCT00967057 Phase 3
38 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3
39 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3
40 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3
41 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3
42 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Completed NCT00002766 Phase 3
43 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3
44 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
45 Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission Completed NCT00002534 Phase 3
46 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
47 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
48 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
49 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
50 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3

Search NIH Clinical Center for Acute T Cell Leukemia

Genetic Tests for Acute T Cell Leukemia

Genetic tests related to Acute T Cell Leukemia:

id Genetic test Affiliating Genes
1 T-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for Acute T Cell Leukemia

MalaCards organs/tissues related to Acute T Cell Leukemia:

39
T Cells, Endothelial, B Cells

Publications for Acute T Cell Leukemia

Articles related to Acute T Cell Leukemia:

(show all 28)
id Title Authors Year
1
Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia inA vivo in a mouse xenogtraft model. ( 27998762 )
2016
2
Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. ( 27756877 )
2016
3
Articulatin-D induces apoptosis via activation of caspase-8 in acute T-cell leukemia cell line. ( 27868169 )
2016
4
CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. ( 26058075 )
2015
5
Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells. ( 24394624 )
2014
6
Mir-55 inhibition can reduce cell proliferation and induce apoptosis in Jurkat (Acute T cell Leukemia) cell line. ( 25598954 )
2014
7
Effects of hydroxylated resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line: Prooxidative potential of hydroxylated resveratrol analogs. ( 24398169 )
2014
8
Conversion of estrone to 17 beta-estradiol in Jurkat acute T cell leukemia Hut-78 T- and Raji B lymphoma cell lines in vitro. ( 23540283 )
2013
9
Combined treatment with fenretinide and indomethacin induces AIF-mediated, non-classical cell death in human acute T-cell leukemia Jurkat cells. ( 22387538 )
2012
10
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. ( 20008304 )
2010
11
Complete regression of massive cardiac involvement associated with acute T cell leukemia following chemotheraphy. ( 17320483 )
2008
12
Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. ( 16502262 )
2006
13
CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. ( 16332967 )
2006
14
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). ( 15774621 )
2005
15
Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation. ( 16266918 )
2005
16
Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. ( 14715100 )
2003
17
A novel post-transcriptional splicing form of the acute T cell leukemia proto-oncogene Lmo2. ( 18763096 )
2001
18
Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T-cell receptor beta chain in an acute T-cell leukemia. ( 8545129 )
1995
19
Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. ( 1371092 )
1992
20
Acute T-cell leukemia/lymphoma mimicking Hodgkin's disease with secondary HTLV I seroconversion. ( 2208004 )
1990
21
Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. ( 2546621 )
1989
22
Constitutive expression and abnormal glycosylation of transferrin receptor in acute T-cell leukemia. ( 2582441 )
1989
23
A case of CD3+, CD4-, CD8-, WT31- acute T-cell leukemia. ( 2787596 )
1989
24
Cyclosporine A and acute T cell leukemia in the rat. ( 3164536 )
1988
25
Childhood primary cutaneous non-T/non-B lymphoma followed by acute T-cell leukemia. ( 3486034 )
1986
26
T-lymphoblasts with erythropoietic helper function in acute T-cell leukemia. ( 2978965 )
1986
27
t(11;19)(q23;p11) in a child with acute T-cell leukemia. ( 3855377 )
1985
28
Human serum thymic factor in detecting acute T cell leukemia. ( 311636 )
1978

Variations for Acute T Cell Leukemia

ClinVar genetic disease variations for Acute T Cell Leukemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.136dupA (p.Ile46Asnfs) duplication Pathogenic rs387906351 GRCh37 Chromosome 1, 85736511: 85736511
2 BAX NM_138761.3(BAX): c.199G> A (p.Gly67Arg) single nucleotide variant Pathogenic rs398122513 GRCh37 Chromosome 19, 49459056: 49459056
3 BAX NM_138761.3(BAX): c.115_121delGGGGGGG (p.Gly39Argfs) deletion Pathogenic rs398122842 GRCh37 Chromosome 19, 49458972: 49458978

Copy number variations for Acute T Cell Leukemia from CNVD:

7 (show top 50) (show all 91)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21835 1 16200000 23900000 Copy number CHD5 T-cell acute lymphoblastic leukemia
2 21836 1 16200000 23900000 Copy number HES2 T-cell acute lymphoblastic leukemia
3 21837 1 16200000 23900000 Copy number HES3 T-cell acute lymphoblastic leukemia
4 32217 1 34600000 44100000 Copy number T-cell acute lymphoblastic leukemia
5 34248 1 5400000 7200000 Deletion T-cell acute lymphoblastic leukemia
6 38166 10 1 3800000 Copy number T-cell acute lymphoblastic leukemia
7 41844 10 24600000 31300000 Copy number ADARB2 T-cell acute lymphoblastic leukemia
8 41845 10 24600000 31300000 Copy number PFKP T-cell acute lymphoblastic leukemia
9 41846 10 24600000 31300000 Copy number PITRM1 T-cell acute lymphoblastic leukemia
10 41847 10 24600000 31300000 Copy number WDR37 T-cell acute lymphoblastic leukemia
11 46873 10 87900000 92900000 Loss PTEN T-cell acute lymphoblastic leukemia
12 48336 11 1 2800000 Gain IGF2 T-cell acute lymphoblastic leukemia
13 48337 11 1 2800000 Gain hsa-mir-675 T-cell acute lymphoblastic leukemia
14 48490 11 1 52900000 Duplication T-cell acute lymphoblastic leukemia
15 53563 11 31000000 36400000 Copy number WT1 T-cell acute lymphoblastic leukemia
16 57103 11 63100000 67100000 Gain MAP4K2 T-cell acute lymphoblastic leukemia
17 57104 11 63100000 67100000 Gain RASGRP2 T-cell acute lymphoblastic leukemia
18 60336 11 85300000 87900000 Loss PICALM T-cell acute lymphoblastic leukemia
19 60878 11 92800000 110400000 Copy number ATM T-cell acute lymphoblastic leukemia
20 61471 12 1 14800000 Deletion T-cell acute lymphoblastic leukemia
21 61531 12 1 35400000 Duplication T-cell acute lymphoblastic leukemia
22 61611 12 10000000 12600000 Loss CDKN1B T-cell acute lymphoblastic leukemia
23 61613 12 10000000 12600000 Loss hsa-mir-614 T-cell acute lymphoblastic leukemia
24 61779 12 10100000 14800000 Copy number CDKN1B T-cell acute lymphoblastic leukemia
25 74382 13 105800000 109100000 Gain TNFSF13B T-cell acute lymphoblastic leukemia
26 78375 13 50900000 55300000 Deletion DLEU7 T-cell acute lymphoblastic leukemia
27 78376 13 50900000 55300000 Deletion KCNRG T-cell acute lymphoblastic leukemia
28 82826 14 15600000 23600000 Deletion T-cell acute lymphoblastic leukemia
29 88309 6 135544145 135582003 Copy number MYB T-cell acute lymphoblastic leukemia
30 104069 16 66700000 70800000 Deletion CTCF T-cell acute lymphoblastic leukemia
31 108732 17 22200000 28800000 Duplication T-cell acute lymphoblastic leukemia
32 109390 17 25800000 31800000 Copy number NF1 T-cell acute lymphoblastic leukemia
33 109749 17 28800000 35400000 Deletion T-cell acute lymphoblastic leukemia
34 111430 17 3600000 6800000 Loss NALP1 T-cell acute lymphoblastic leukemia
35 115247 17 55600000 58400000 Gain MSI2 T-cell acute lymphoblastic leukemia
36 115248 17 55600000 58400000 Gain VEZF1 T-cell acute lymphoblastic leukemia
37 115617 17 58400000 59900000 Gain MAP3K3 T-cell acute lymphoblastic leukemia
38 115618 17 58400000 59900000 Gain SMURF2 T-cell acute lymphoblastic leukemia
39 115619 17 58400000 59900000 Gain hsa-mir-633 T-cell acute lymphoblastic leukemia
40 115878 17 59900000 64600000 Gain PRKCA T-cell acute lymphoblastic leukemia
41 116600 17 68400000 72200000 Gain GPR142 T-cell acute lymphoblastic leukemia
42 116601 17 68400000 72200000 Gain GPRC5C T-cell acute lymphoblastic leukemia
43 121278 18 41800000 46400000 Loss SMAD4 T-cell acute lymphoblastic leukemia
44 124174 19 1 6900000 Gain MKNK2 T-cell acute lymphoblastic leukemia
45 131214 19 53800000 57600000 Gain FUT2 T-cell acute lymphoblastic leukemia
46 131215 19 53800000 57600000 Gain RASIP1 T-cell acute lymphoblastic leukemia
47 133723 19 6900000 12600000 Gain INSR T-cell acute lymphoblastic leukemia
48 133733 19 6900000 13900000 Deletion T-cell acute lymphoblastic leukemia
49 140125 2 19200000 27900000 Copy number NCOA1 T-cell acute lymphoblastic leukemia
50 140126 2 19200000 27900000 Copy number TP53I3 T-cell acute lymphoblastic leukemia

Expression for Acute T Cell Leukemia

Search GEO for disease gene expression data for Acute T Cell Leukemia.

Pathways for Acute T Cell Leukemia

GO Terms for Acute T Cell Leukemia

Sources for Acute T Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....